Thyroid stimulating hormone (TSH) concentrations and menopausal status in women at the mid-life: SWAN by Sowers, MaryFran R. et al.
 








© 2003 Blackwell Publishing Ltd
 
Blackwell Science, LtdThyroid stimulating hormone (TSH) concentrations and 
menopausal status in women at the mid-life: SWAN
 
MaryFran Sowers*, Judy Luborsky†, Craig Perdue*, 















New England Research Institutes, Watertown, MA, 
USA 
 
(Received 21 March 2002; returned for revision 15 April 2002; 






We evaluated menopausal symptoms,
menstrual cycle bleeding characteristics and repro-
ductive hormones for their associations with thyroid
stimulating hormone (TSH) concentrations in women




This report is from the baseline evaluation
of the Study of Women’s Health Across the Nation
(SWAN), a community-based multiethnic study of the
natural history of the menopausal transition. Enrollees
were 42–52 years old (pre- and early perimenopausal)





 = 3242). Enrollees were interviewed
about self-reported diagnosed hypo- and hyperth-
yroidism or thyroid treatment, menopausal symptoms
and menstrual cycle bleeding characteristics. Serum





There were 6·2% of women with TSH >
5·0 mIU/ml and 3·2% with TSH < 0·5 IU/ml, cutpoints
that have been used to encompass clinical and sub-
clinical hypo- and hyperthyroidism, respectively.
African American women had significantly lower mean
TSH concentrations than Caucasian, Hispanic and
Chinese women. Of the more than 15 menopause
symptoms evaluated, only fearfulness was associated









 < 0·02). Women with TSH values outside the
range of 0·5–5·0 mIU/ml were more likely to report




 = 0·004 for
both) than women within that range. FSH, SHBG, dehy-
droepiandrosterone sulphate (DHEA-S), testosterone,





In mid-aged women, there was a 9·6%
prevalence of TSH values outside the euthyroid range
of 0·5–5·0 mIU/ml. Although TSH was associated with
bleeding length and self-reported fearfulness, it was
not associated with indicators of the menopausal tran-
sition, including menopausal stage defined by bleed-
ing regularity, menopausal symptoms or reproductive
hormone concentrations.
 
In women, reports of hypothyroidism prevalence have ranged









1995) while the reported prevalence of hyperthyroidism has

























., 2000), with some of the variation
associated with different disease definitions. There are few
studies of thyroid status and the menopause transition, although
the prevalence of thyroid disease, particularly hypothyroidism,

















Furthermore, no published studies compare thyroid stimulating
hormone (TSH) concentrations in multiple race/ethnic groups.
The only study that includes African American women focused





Thyroid status may contribute to the variation in symptom
frequency and intensity as well as in bleeding patterns during the




., 1995). It has long been
recognized clinically that thyroid disease is associated with
menstrual cycle disturbances (Stoffer, 1982; Wilson & Foster,
1985; Koutras, 1995; Doufas & Mastorakos, 2000) although the








. (1993) have found that
menstrual irregularities may precede other clinical features of
thyroid dysfunction and argue that thyroid function should be
evaluated in perimenopausal women with menstrual irregularity.
Hyper- and hypothyroid states may cause marked alterations
in steroid metabolism. Hyperthyroidism has been associated with
decreased free testosterone concentration, and, in some instances,
a decrease in oestradiol, as well as a marked increase in SHBG
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., 1999). FSH concentrations may also be increased. In con-
trast, hypothyroidism results in decreased prevalence of 5-alpha
metabolites of androgens, a decrease in the 2-hydroxylation of
oestrone and an increase in peripheral aromatization of andro-




., 1990). Thus, in repro-
ductive endocrine studies, altered thyroid status could potentially
contribute to variations in hormone levels commonly associated
with the menopause transition.
The Study of Women’s Health Across the Nation (SWAN) is
a community-based study of the natural history of the menopau-
sal transition in a multiethnic population. SWAN provides a
unique opportunity to address questions about thyroid status
because it was developed expressly to distinguish the endocrine,
physical and psychosocial characteristics of the menopausal tran-
sition. This paper identifies the prevalence of self-reported diag-
nosis of hypo- and hyperthyroidism and treatment among women
aged 42–52 years. It also evaluates serum TSH concentration and
its association with reproductive hormone concentrations, men-
opausal symptoms and menstrual bleeding characteristics in the






The SWAN is a prospective, multiethnic, multidisciplinary study
of the natural history of the menopausal transition in 3302
women. SWAN study sites are located in seven US locations:
Boston, Chicago, the Detroit area, Los Angeles, Newark, Pitts-
burgh and Oakland, California. A two-stage recruitment process
was used to recruit women. First, in 1995–97, a 15-minute survey
was used to collect limited health-related data and compile a list-
ing of women who could be sampled for the longitudinal study.
Women eligible for the survey were aged 40–55 years, spoke
English or one of the other study languages (Spanish, Japanese,
Cantonese) and were members of the target racial /ethnic group
identified by each site. During the second stage, each clinical
centre recruited community-based samples of approximately 450
women from their local first-stage sample. These women were
42–52 years, pre- or early perimenopausal (defined as having had
at least one menstrual period in the previous 3 months), and not
using exogenous hormone preparations affecting ovarian func-
tion. Recruitment was stratified at each site to achieve a desig-
nated proportion of non-Hispanic Caucasian women and a
minority group (African American, Chinese, Hispanic or
Japanese). Additional information about the eligibility criteria,
sampling frames and characteristics of participants has been




., 2000). All study activities





A common protocol was used by the seven clinical sites. Self-





indicating menses had occurred in the past 3 months but had





had occurred in the past 3 months with no decreased predictability.
Age, smoking behaviour and ethnicity were also self-reported.
Primary race/ethnicity was self-defined.
Women reported how frequently they experienced each of
15 menopause symptoms including vasomotor symptoms and
forgetfulness in the 2 weeks prior to interview, with responses
ranging from 1 (not at all) to 5 (daily) for each item (Neugarten &









symptomatology was assessed with the Center for Epidemiolog-
ical Studies Depression (CES-D) scale, a well-validated 20-item
scale with four-level responses indicating frequency of experi-
encing each symptom in the past week (Radloff, 1977). It has
been shown to correlate well with other depressive symptom
questionnaires and with diagnostic interviews that assess severity





Women were asked if they had been diagnosed as having an
underactive thyroid or overactive thyroid and were asked to report




A blood sample was taken from enrollees following an 8-hour
fast during days 2–7 of the follicular phase of the menstrual cycle.
Hormone assays were conducted in the SWAN Endocrine
Laboratory at the University of Michigan using an ACS-180 auto-
mated analyser (Bayer Diagnostics Corp., 115 Norwood Park
South, Norwood, MA 02062, USA). TSH concentration was
assessed using the commercial ACS:180 TSH assay (Bayer
Diagnostics), which is a two-site sandwich chemiluminescent
assay using a DMAE-labelled monoclonal mouse antibody and
a polyclonal sheep antibody coupled to paramagnetic particles.
Inter- and intra-assay coefficients of variation (CVs) were 9·0%
and 1·9%, respectively. The cutpoints of < 0·5 mIU/ml and
> 5·0 mIU/ml were used to establish boundaries for being
euthyroid (Wilson & Foster, 1985). Table 1 shows the frequency
of TSH values outside these boundaries that may be related to
various definitions of subclinical and clinical disease. No additional
markers of thyroid status, including T3, T4 or autoantibodies,
were assayed.
Serum oestradiol concentrations were measured with a mod-




-6) immunoassay. Inter- and intra-
assay CVs averaged 10·6% and 6·4%, respectively, over the assay
range. Serum FSH concentrations were measured with a two-site
chemiluminometric immunoassay that uses constant amounts of
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Each antibody is directed to different regions on the beta subunit
(one coupled to paramagnetic particles and the other labelled
with DMAE) with specificity for intact FSH. Inter- and intra-
assay CVs were 12·0% and 6·0%, respectively. Testosterone con-
centrations were evaluated with the ACS:180 total testosterone
assay modified to increase precision in the lower ranges. The
resulting assay includes competitive binding of a DMAE-
labelled testosterone derivative to a rabbit polyclonal antitesto-
sterone antibody premixed with monoclonal antirabbit IgG
antibody immobilized on the solid-phase paramagnetic particles.
Inter- and intra-assay CVs were 10·2% and 5·1%, respectively,
for this modified assay. The free androgen index (FAI) was
derived to address the activity of the nonbound androgen:




 SHBG). The free oestradiol index (FEI)

















two-site chemiluminescent assay for SHBG involved competitive
binding of DMAE-labelled SHBG to a commercially available
rabbit anti-SHBG antibody and a solid phase of goat antirabbit
IgG conjugated to paramagnetic particles. Inter- and intra-assay
CVs were 9·9% and 6·1%, respectively. The dehydroepiandros-
terone sulphate (DHEA-S) assay was developed on-site using








Of the 3302 women, there were the following exclusions: 16
women had no TSH values, five had very high TSH values with
uncertain data quality, and 46 did not respond to questions con-
cerning thyroid status or thyroid medication, including seven
women who failed to answer either question. Data management
and analysis were conducted with SAS v.6·12 (SAS Institute,
Cary, NC, USA).
Univariate statistics were calculated for continuous variables
including TSH, other hormones, body mass index (BMI) and age.
For purposes of multivariable analyses, a natural log (of FSH and
reproductive hormones) or square root (for SHBG and TSH)
transformation was applied to address skewness or to satisfy the
modelling assumptions such as normally distributed residuals. A
kappa statistic was used to show agreement between being treated
for thyroid disease and having a TSH in the euthyroid range.
We correlated TSH and reproductive hormones and reported
the partial correlation coefficients following adjustment for im-
portant covariates. Important covariates were age, race/ethnicity,
clinical site and smoking behaviour. All analyses were performed
both with and without women who reported taking thyroid
medication. Adjustment for day of cycle had no impact on the
observed associations.
The least squared mean (LSmean) TSH concentrations for
pre- and perimenopausal women was calculated using analysis
of covariance within the SAS PROC GLM procedure. Multiple
variable logistic regression was used to evaluate the association
of TSH concentrations as a continuous independent variable and
menopause status as the dichotomous dependent variable, after
including appropriate covariates.






-test statistic of homo-
geneity were used to relate menstrual characteristics, premen-
strual and menopausal symptoms with TSH categorized as
< 0·5 mIU/ml, 0·5–5·0 mIU/ml or > 5·0 mIU/ml. Ordinal logistic
regression was used to relate multilevel menopause symptoms
or bleeding characteristics to TSH concentrations (continuous)
or TSH categories as independent variables. For example, this
approach was used when bleeding flow lengths, reported at
multiple levels (1–2 days, 3–7 days and > 7 days in the 2 weeks
prior to interview), were associated with TSH categories as the
independent variable. The proportionality assumption of ordinal
logistic regression was met. Model fit, including appropriateness





The mean and median TSH concentrations in these pre- and per-
imenopausal women, aged 42–52 years, were 2·4 (2·2 SD) and
1·9 mIU/ml (1·3–2·8 IQR), respectively, including treated
women. When women treated with thyroid medication were
excluded, the mean (SD) and median (IQR) TSH concentrations





 = 104) of women with TSH values less than




 = 201) of women with TSH values
greater than 5·0 mIU/ml (see Table 2).




 = 248) of women characterized them-





 = 117) of women who characterized themselves as having an
Table 1 Distribution of TSH concentrations in pre- and perimenopausal 





All women Untreated women 
Frequency Percent Frequency Percent
< 0·1 38 1·17 17 0·55
0·1–0·29 32 0·99 41 0·78
0·3–0·49 34 1·05 72 1·00
0·5–5·0 2937 90·59 2852 92·39
5·01–10 154 4·75 127 4·11
10·01–15·0 28 0·86 24 0·78
15·01–20·0 9 0·28 6 0·19
> 20* 10 0·31 6 0·19

















overactive thyroid (see Table 3). Of the 4·7% of women who
reported thyroid medication use, 58% (90 out of 155) had TSH
concentrations within the euthyroid range. Of those treated for
an underactive thyroid, 48% (58 out of 120) had TSH values out-
side the normal range. Of those treated for an overactive thyroid,
34% (12 out of 35) had TSH values outside the normal range.
As shown in Table 4, African American women were propor-
tionately more likely to have TSH values less than 0·5 mIU/ml
while Caucasian, Hispanic and Chinese women were more likely




 < 0·0001). Figure 1
shows the mean absolute TSH concentrations as well as the least
squared means of the transformed TSH concentrations by race/




Characteristic TSH < 0·5 mIU/ml 0·5–5·0 mIU/ml (euthyroid) TSH > 5·0 mIU/ml
All women (n = 3242)
Mean TSH (SD) (mIU/ml) 0·2 (0·16) 2·0 (0·9) 8·7 (4·6)
Median TSH (IQR) 0·18 (0·03–0·3) 1·8 (1·33–2·62) 6·7 (5·9–9·5)
Untreated women (n = 3087)
Mean TSH (SD) (mIU/ml) 0·24 (0·15) 2·05 (0·9) 8·36 (4·2)
Median TSH (IQR) 0·2 (0·1–0·4) 1·8 (1·3–2·6) 6·7 (5·9–9·2)
Total number of women 104 (3·2%) 2937 (90·6%) 201 (6·2%)
SD, standard deviation; IQR, interquartile range.




Characteristic TSH < 0·5 mIU/ml 0·5–5·0 mIU/ml (euthyroid) TSH > 5·0 mIU/ml kappa*
Self-report thyroid state
Underactive thyroid 30 (28·8%) 165 (5·6%) 53 (26·4%) 0·09
Euthyroid 59 (56·7%) 2682 (91%) 134 (66·7%)
Overactive thyroid 15 (14·4%) 88 (3·0%) 14 (7·0%)
Using thyroid medication
For underactive thyroid 26 (22·0%) 62 (51·6%) 32 (26·6%) 0·21
For overactive thyroid 6 (17·1%) 23 (65·7%) 6 (17·1%)
*Values of kappa < 0·40 represent poor agreement between self-reported status and laboratory-defined status.
  
  
TSH < 0·5 mIU/ml
0·5–5·0 mIU/ml 
(euthyroid) TSH > 5·0 mIU/ml
All women
African American 40 (4·3%) 844 (92·0%) 33 (3·6%)
Hispanic 5 (1·7%) 261 (91·9%) 18 (6·3%)
Chinese 8 (3·3%) 219 (90·1%) 16 (6·6%)
Japanese 10 (3·6%) 264 (94·9%) 4 (1·4%)
Caucasian 41 (2·7%) 1349 (88·7%) 130 (8·5%)
Untreated women
African American 30 (3·4%) 822 (93·9%) 23 (2·6%)
Hispanic 4 (1·4%) 255 (92·4%) 17 (6·2%)
Chinese 6 (2·6%) 210 (92·1%) 12 (5·3%)
Japanese 8 (2·9%) 262 (96·0%) 3 (1·1%)
Caucasian 24 (1·7%) 1303 (90·8%) 108 (7·5%)
Table 4 Frequency (number and percent) of women 
in TSH categories used as a proxy for thyroid status, 




M. Sowers et al.
 










ethnic groups. African American women had a significantly
lower LSmean TSH concentration than all groups except for
Japanese women. In turn, the LSmean TSH concentrations of
Japanese women were significantly lower than TSH concentrations
of Caucasian women but not of the Chinese or Hispanic women.
TSH concentrations increased with age even among women




 < 0·04). For each 5-
year increase in age, there was a 3·5% increase in TSH concen-
trations. BMI and smoking classification were not related to the
TSH concentrations after adjusting for age, clinical site and race/
ethnicity (data not shown).
 
TSH and menopause-related symptoms
 
Two symptoms were associated with TSH concentrations.
Frequency of feeling fearful in the 2 weeks prior to interview was




 < 0·008). Women who
reported feeling fearful were disproportionately represented in




 < 0·02). Women who self-
reported less sexual interest had a slightly lower adjusted mean
TSH concentration than women who maintained their level of









TSH concentrations were not associated with self-reported
sleep disturbances, stiffness, cold sweats, hot flashes, night
sweats, vaginal dryness, urinary incontinence, irritability, feeling
blue, tense or nervous, having mood changes, forgetfulness or





 Women classified as having depressive symptomatology










Patterns of menstrual bleeding and reproductive hormones
 
TSH concentrations were modestly associated with usual length
of menstrual flow in the year prior to interview (see Table 5).
Women outside the TSH range of 0·5–5·0 mIU/ml were more





The adjusted TSH means were 1·98, 2·11, 2·34 and 3·96 mIU/
ml for flows lasting 1–2 days, 3–7 days, more than 7 days, and




 < 0·02). These results remained
constant when treated women were excluded.
TSH concentrations were not significantly associated with










































































 < 0·27), nor with their related SHBG-indices, FAI and FEI,





In these women, aged 42–52 years, 9·4% had TSH values outside
the range of 0·5–5·0 mIU/ml. Almost half of the women who
reported being treated with thyroid medication did not have a






There was no significant difference in TSH concentrations




















SWAN is a longitudinal study, ultimately we will be able to
evaluate the impact of each stage of the menopause transition on




menopause status on thyroid status.
We observed no association of TSH with reproductive hor-
mone concentrations, including oestradiol, although it has been
Fig. 1 The LSmeans for TSH (open bars, transformed; solid bars, 
untransformed) by self-reported race/ethnicity designation, following 




menstrual flow TSH < 0·5 mIU/ml
0·5–5·0 mIU/ml
(euthyroid) TSH > 5·0 mIU/ml P-value of χ2
Usual flow length 0·004
1–2 days 6 (5·7%) 57 (1·9%) 6 (2·9%)
3–7 days 89 (85·5%) 2718 (92·5%) 173 (86·0%)
> 7 days 8 (7·7%) 158 (5·3%) 22 (10·9%)
Table 5 The frequency of usual menstrual flow 

















reported that oestradiol concentrations increase TSH concentra-
tions by antagonizing the feedback inhibition of TSH synthesis
by T3 (Yarwood et al., 1993). Overlie et al. (1999) reported
significantly higher TSH concentrations in the luteal phase com-
pared with the follicular phase (data not given), although others
have reported that TSH concentrations did not vary according to
menstrual phase (Sawin et al., 1978). In SWAN, more than 85%
of blood draws were completed in days 2–7 of the follicular
phase, the time period where there is less cyclic variation, avoid-
ing potential misinterpretation of information. However, import-
ant differences may occur in the luteal phase and this could not
be assessed.
We observed an association between the length of menstrual
flow in the previous year and TSH concentrations. Because
women were recruited to SWAN based on their menstrual charac-
teristics, it was not possible to evaluate the association between
TSH concentrations and either oligo- or amenorrhoea. Women
with TSH > 5·0 mIU/ml were twice as likely to report having
menstrual bleeding lasting at least 8 days than were euthyroid
women. Although several case reports suggest an association
between menstrual dysfunction and thyroid status (Wilansky &
Greisman, 1989; Higham & Shaw, 1992; Joshi et al., 1993;
Massoudi et al., 1997), others have found no association of
TSH, T4 and T3 levels with regular and irregular cycles (Krassas
et al., 1999).
While there was no measure of anxiety in this study, feeling
fearful was associated with TSH concentrations. Psychiatric
symptoms, especially anxiety, are commonly reported prior to
treatment of hyperthyroidism and exclusion of hyperthyroidism
is recommended prior to making a psychiatric diagnosis (Kathol
& Delahunt, 1986; Stern et al., 1996). Some studies suggest
that elevated anxiety persists in patients with Graves’ disease
(Paschke et al., 1990; Harsch et al., 1992) or that panic disorder
precedes the onset of hypothyroidism (Matsubayashi et al., 1996).
We found no association of depressed mood with TSH concen-
tration, corroborating another report that depression was not sig-
nificantly associated with thyroid status (Ballinger et al., 1987).
There were significant racial/ethnic differences in mean TSH
concentrations in this sample with significantly lower mean TSH
concentrations among African Americans and Japanese women.
There is a paucity of literature on racial/ethnic variation in TSH
levels but our results are consistent with the sparse literature.
In two studies, Blacks had significantly lower levels of TSH and
thyroid autoantibodies compared to Caucasians (American Psychi-
atric Association, 1987; Schectman et al., 1991) and a third study
found that Hispanics had higher levels of thyroid autoantibodies
compared to Blacks (Bowry et al., 1984). The importance of
these ethnic variations is unknown, but may be related to ethnic
variations in the prevalence of some autoimmune diseases or life-
style factors that could include difference in food containing
iodine.
While SWAN is uniquely positioned to characterize the men-
opause transition and thyroid status in a large community-based
population, this report of the baseline cross-sectional data has
limitations. SWAN is a study of the natural menopause whose
eligibility was based on the presence of menstrual bleeding,
thereby precluding the inclusion of women with hysterectomy,
premature menopause, or highly variable bleeding, all conditions
that have been related to thyroid status. Second, the data pres-
ented cannot be interpreted as representative of the entire transi-
tion. Continued evaluation of TSH concentrations in SWAN
enrollees will allow us to relate baseline and subsequent thyroid
status to the progression of menopause characteristics including
symptoms and bleeding patterns. Third, TSH concentrations are
only proxy measures. Although TSH has been widely used to
evaluate populations from a screening perspective, measurement
of T3 and T4, thyroid autoantibodies, or TSH alpha and beta
subunits, would be required to more definitively define thyroid
status. Fourth, in common with other glycoprotein hormones,
TSH appears to have some episodic and circadian variation. This
variability was addressed, in part, by employing phlebotomy proto-
cols whereby blood was drawn in a fasting state in the morning
(usually before 1100 h) and in days 2–7 of the menstrual cycle
(Kasim & Bessman, 1984; Wilson & Foster, 1985; Samuels et al.,
1990). Finally, this report used TSH values of 0·5–5·0 mIU/ml
as indicative of the normal range with the recognition that values
outside that range were much more likely to encompass both clin-
ical and subclinical disease. This was done with the understand-
ing that additional data, such as T3/ T4 values and antibodies,
were not available to specifically characterize thyroid status and
that, in the absence of such additional supporting information,
an alternative nosology would be open to challenge.
In summary, despite a relatively high prevalence (9·6%) of
impaired thyroid status, there was little association with measures
of the earliest stage of the menopause transition. Although TSH
was associated with bleeding length and self-reported fearfulness,
it was not associated with other measures thought to characterize
menopausal symptoms or with reproductive hormone concentra-
tions. Nonetheless, the marked frequency with which TSH values
were outside the normal range is consistent with the recommen-
dations that screening for thyroid status would be cost-effective
(Danese et al., 1996). However, based on these findings, any move
towards screening should not be predicated on women reporting
symptoms associated with the menopausal transition or having
FSH values thought to be indicative of the menopausal transition.
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